Inhibiting lncRNA NEAT1 Increases Glioblastoma Response to TMZ by Reducing Connexin 43 Expression

Cancer Reports, Год журнала: 2024, Номер 7(10)

Опубликована: Окт. 1, 2024

ABSTRACT Objectives Glioblastoma multiforme (GBM) is considered the most assailant subtype of gliomas, presenting a formidable obstacle because its inherent resistance to temozolomide (TMZ). This study aimed characterize function lncRNA NEAT1 in facilitating advancement gliomas. Methods The expression level glioma tissues and cells was detected by qRT‐PCR. RNA interference experiment, cell proliferation assay, FITC/PI detection immunoblotting, bioinformatics prediction, double luciferase reporter gene immunoprecipitation (RIP) SLDT assay correlation analysis clinical samples were performed explore regulatory effects NEAT1, miR‐454‐3p Cx43 their role malignant progression GBM. vivo investigated an intracranial tumor formation experiment mice. Results results showed that recurring gliomas displayed elevated levels compared primary suppression led restoration sensitivity GBM TMZ. functioned as competitive endogenous against miR‐454‐3p. Connexin 43 identified target. found regulate gap junctional intercellular communication modulating 43, thereby impacting response TMZ chemotherapy. Downregulation resulted enhanced chemosensitivity extended survival Conclusions Overall, these indicated NEAT1/miR‐454‐3p/Connexin pathway influences could offer potential new strategy for treating

Язык: Английский

---

Cancer neuroscience and glioma: clinical implications

Acta Neurochirurgica, Год журнала: 2025, Номер 167(1)

Опубликована: Янв. 3, 2025

Abstract In recent years, it has been increasingly recognized that tumor growth relies not only on support from the surrounding microenvironment but also tumors capacity to adapt – and actively manipulate its niche. While targeting angiogenesis modulating local immune environment have explored as therapeutic approaches, these strategies yet yield effective treatments for brain remain under refinement. More recently, nervous system itself a critical environmental cancer, with extensive neuro-tumoral interactions observed both intracranially in extracranial sites containing neural components. brain, between glioma cells well metastatic lesions components clinical implications diagnostics, risk assessments, neurological sequelae, development of innovative therapeutics. Here, we review dynamics, emphasizing aspects relevant neurosurgical practice.

Язык: Английский

---

Neuroplasticity in Diffuse Low-grade Gliomas: Backward Modelling of Brain-tumor Interactions Prior to Diagnosis is Needed to Better Predict Recovery after Treatment

Current Neurology and Neuroscience Reports, Год журнала: 2025, Номер 25(1)

Опубликована: Янв. 9, 2025

Язык: Английский

---

The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma

BMC Cancer, Год журнала: 2025, Номер 25(1)

Опубликована: Фев. 20, 2025

The discovery of cellular tumor networks in glioblastoma, with routes malignant communication extending far beyond the detectable margins, has highlighted potential supramarginal resection strategies. Retrospective data suggest that these approaches may improve long-term disease control. However, their application is limited by proximity critical brain regions and vasculature, posing challenges for validation randomized trials. Anterior temporal lobectomy (ATL) a standardized surgical procedure commonly performed patients pharmacoresistant lobe epilepsy. Translating ATL approach from epilepsy surgery to neuro-oncological field provide model investigating glioblastomas located anterior lobe. ATLAS/NOA-29 trial prospective, multicenter, multinational, phase III controlled designed compare standard gross-total (GTR) newly-diagnosed glioblastoma. primary endpoint overall survival (OS), superiority defined significant improvements OS non-inferiority co-primary endpoint, quality life (QoL; "global health" domain European organization research treatment cancer (EORTC) QLQ-C30 questionnaire). Secondary endpoints include progression-free (PFS), seizure outcomes, neurocognitive performance, longitudinal assessment six selected domains EORTC BN20 questionnaires. Randomization will be intraoperatively upon receipt fresh frozen section result. A total 178 1:1 ratio over 3-year recruitment period followed-up minimum 3 years. supervised Data Safety Monitoring Board, an interim safety analysis planned after 57th patient assess differences modified Rankin Scale (mRS) scores between arms 6 months resection. Assuming median improvement 17 27.5 months, powered at > 80% detect two-sided log-rank test 5% significance level. aims determine whether provides superior outcomes equal patients' Qol compared GTR potentially establishing as choice isolated glioblastoma redefining care this population. German Clinical Trials Register (DRKS00035314), registered on October 18, 2024.

Язык: Английский

---

Advanced brain tumor segmentation using DeepLabV3Plus with Xception encoder on a multi-class MR image dataset

Multimedia Tools and Applications, Год журнала: 2025, Номер unknown

Опубликована: Фев. 21, 2025

Язык: Английский

---

Commentary: Resting State Functional Networks in Gliomas: Validation With Direct Electrical Stimulation Using a New Tool for Planning Brain Resections

Neurosurgery, Год журнала: 2024, Номер unknown

Опубликована: Июнь 13, 2024

Язык: Английский

---

Understanding brain cancer and exploiting its vulnerabilities

Molecular Oncology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 25, 2024

Язык: Английский

---